CTI Biopharma Corp reports results for the quarter ended in June - Earnings Summary

CTI Biopharma

08/08/2022 23:01

* CTI Biopharma Corp  CTIC.OQ  reported a quarterly adjusted
loss
of 21 cents​​ per share for the quarter ended in June. The mean
expectation of seven analysts for the quarter was for a loss
of 20 cents per share.
    * Revenue was $12.33 million​; analysts expected $9.10
million. 
    * CTI Biopharma Corp's reported EPS for the quarter was a
loss
of 21 cents​.
    * The mean earnings estimate of analysts had risen by
about 24.8%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * CTI Biopharma Corp shares had risen by 24.5% this
quarter and
gained 199.6% so far this year.
    * The company reported a quarterly loss of $22.65 million.
    * Wall Street's median 12-month price target for CTI
Biopharma
Corp is $10.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 8
at 10:01 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.20          -0.21          Missed
 Mar. 31 2022      -0.41          -0.37          Beat
 Dec. 31 2021      -0.28          -0.38          Missed
 Sep. 30 2021      -0.25          -0.26          Missed